APA (7th ed.) Citation

Nelson, D. R., Cooper, J. N., Lalezari, J. P., Lawitz, E., Pockros, P. J., Gitlin, N., . . . Hughes, E. A. (2015). All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study. Hepatology (Baltimore, Md.), 61(4), 1127-1135. https://doi.org/10.1002/hep.27726

Chicago Style (17th ed.) Citation

Nelson, David R., et al. "All‐oral 12‐week Treatment with Daclatasvir Plus Sofosbuvir in Patients with Hepatitis C Virus Genotype 3 Infection: ALLY‐3 Phase III Study." Hepatology (Baltimore, Md.) 61, no. 4 (2015): 1127-1135. https://doi.org/10.1002/hep.27726.

MLA (9th ed.) Citation

Nelson, David R., et al. "All‐oral 12‐week Treatment with Daclatasvir Plus Sofosbuvir in Patients with Hepatitis C Virus Genotype 3 Infection: ALLY‐3 Phase III Study." Hepatology (Baltimore, Md.), vol. 61, no. 4, 2015, pp. 1127-1135, https://doi.org/10.1002/hep.27726.